Asset Manager

Updated:

OncoResponse

OncoResponse, a Houston-based company, was founded in 2015. It focuses on cancer research, particularly immunotherapies and oncology technologies.

OncoResponse

OncoResponse, a Houston-based company, was founded in 2015. It focuses on cancer research, particularly immunotherapies and oncology technologies. The company has secured $137 million in total funding.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Houston

Corporate office

Houston, TX, United States

Additional offices

Seattle, WA, United States

Sector focus

BiotechOncology

Frequently asked questions

What technology does OncoResponse use to discover antibodies?

OncoResponse uses a clinically validated technology platform that isolates authentic human antibodies from B cells of patients who achieved exceptional responses to checkpoint inhibitor therapy (per the firm's website). These antibodies target multiple immunosuppressive myeloid biology targets associated with the tumor microenvironment.

What is the investment stage and structure of OncoResponse?

OncoResponse is a biotech company, not a fund or family office. It is structured to develop its own pipeline of monoclonal antibodies through preclinical research and clinical studies. The firm's financial details, investor base, and funding rounds are not publicly disclosed.

Does OncoResponse collaborate with external partners?

The firm states it makes advancements through collaborators and strategic partnerships, listing current collaborators on its website. However, specific partner names or collaboration details are not publicly available beyond general references.

What is the therapeutic focus of OncoResponse's pipeline?

OnocResponse's pipeline targets immunosuppressive myeloid biology in the tumor microenvironment. The firm aims to remove brakes on immune cells and convert cold tumors into hot tumors that respond to immunotherapy (per the firm's website).

Who leads OncoResponse?

OncoResponse does not publicly name its leadership team, board of directors, or scientific advisory board members on its website. The firm's principals and organizational leadership remain undisclosed in public materials.

Where does OncoResponse operate?

OncoResponse maintains headquarters in Houston, Texas, and has an additional office in Seattle, Washington (per the firm's website). All operations are within the United States.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Houston Asset Manager profiles